Breaking Finance News

Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) has been upgraded to Hold in a report by Zacks Investment Research today.

Zacks Investment Research has upgraded Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) to Hold in a report released on 10/11/2016.

Yesterday Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) traded 6.15% higher at $6.90. The company’s 50-day moving average is $6.67 and its 200-day moving average is $6.59. The last closing price is up 4.69% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 9,785 shares of the stock traded hands, down from an average trading volume of 25,318

See Chart Below

Aeglea Bio Therapeutics Inc (NASDAQ:AGLE)

Aeglea Bio Therapeutics Inc has a 52 week low of $3.89 and a 52 week high of $12.75 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its stock price target, a total of 3 brokers have issued a report on the company. The average stock price target is $16.33 with zero equity analysts rating the company a strong buy, zero equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and lastly zero brokerages rating the company a sell.

General Company Details For Aeglea Bio Therapeutics Inc (NASDAQ:AGLE)

Aeglea BioTherapeutics, Inc. is a biotechnology company. The Company is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its engineered human enzymes are designed to degrade specific amino acids in the blood. Its portfolio of products include AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency. AEB1102 is in Phase I clinical trial in oncology. AEB3103 is an enzyme that degrades the amino acids cysteine/cysteine. AEB2109 is an enzyme that degrades the amino acid methionine to target methionine dependent cancers. AEB4104 is an engineered human enzyme to target the reduction of elevated levels of the amino acid homocystine associated with the IEM classical homocystinuria.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *